GALK1-IN-1

• CAT Number: I012428
• CAS Number: 669718-48-3
• Molecular Formula: C19H20N4O2
• Molecular Weight: 336.39
• Purity: ≥95%
• Synonyms: 2-(1,3-benzoxazol-2-ylamino)spiro[1,6,7,8-tetrahydroquinazoline-4,1′-cyclopentane]-5-one
• IUPAC Name: 2-(1,3-benzoxazol-2-ylamino)spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]-5-one
• InChI: InChI=1S/C19H20N4O2/c24-14-8-5-7-13-16(14)19(10-3-4-11-19)23-17(20-13)22-18-21-12-6-1-2-9-15(12)25-18/h1-2,6,9H,3-5,7-8,10-11H2,(H2,20,21,22,23)
• InChIKey: FDNVTCDQGOVLPM-UHFFFAOYSA-N
• SMILES: C1CCC2(C1)C3=C(CCCC3=O)NC(=N2)NC4=NC5=CC=CC=C5O4

GALK1-IN-1（Cat No.:I012428）is an investigational small molecule inhibitor targeting the enzyme galactokinase 1 (GALK1), which plays a key role in galactose metabolism. By inhibiting GALK1, this compound aims to disrupt the conversion of galactose into glucose, which is crucial for cellular energy production. GALK1-IN-1 is being explored for its potential therapeutic applications in metabolic disorders, such as galactosemia, where the accumulation of galactose leads to toxic effects. Preclinical studies suggest that it could help reduce metabolic imbalances and prevent organ damage associated with these conditions, with clinical trials underway.